Riskpilot← Back to searchSign inGet full accessLabsync AB
ABActiveOrg 5591670376Eksätravägen 46Engineering activities and related technical consultancy · NACE 7112Est. 20180 employees
Revenue 2025
SEK 0
EBITDA margin
—
-114% vs 2024
Equity ratio
81.0%
Financial strength
Net profit 2025
SEK 341K
+4% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -26K | -114% |
| Net profit | SEK 341K | +4% |
| Total assets | SEK 2,8M | +4% |
| Equity | SEK 2,3M | +7% |
| Employees | 0 | — |
Legal name
Labsync AB
Org number
5591670376
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
31 juli 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsult inom biotech- och läkemedelsindustrin. Utför arbete inom kvalitetssäkring, analysutveckling, optimering av arbetsflöden, integration och projektledning.
Address
Eksätravägen 46
Email
johan.stalberg@labsync.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 849 | 511 | 26 | 24 | 0 |
| Staff expenses | — | −123 | −197 | 191 | −0 |
| EBITDA | 2 043 | 320 | −214 | 191 | −26 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 2 043 | 320 | −214 | 191 | −26 |
| Net financials | −1 | −263 | 131 | 154 | 352 |
| Profit before tax | 1 543 | 56 | 143 | 379 | 341 |
| Tax | −319 | −67 | −10 | −52 | — |
| Net profit | 1 224 | −11 | 133 | 328 | 341 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 732 | 3 002 | 2 561 | 2 692 | 2 803 |
| Equity | 2 334 | 2 019 | 2 002 | 2 130 | 2 270 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 638 | 223 | 25 | 63 | 47 |
| Total debt | 638 | 223 | 25 | 63 | 47 |
EBITDA margin
-2579300.0%
This company
15.8%
Market median
-16324784% vs market
20212025
Equity ratio
81.0%
This company
38.2%
Market median
+112% vs market
20212025
Return on equity
15.0%
This company
18.4%
Market median
+18% vs market
20212025
Net profit margin
34083500.0%
This company
8.1%
Market median
+420783851% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Labsync AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Harald Stålberg | Board of Directors | 0 companies |
| Christina Ninalga Stålberg | Deputy Board Member | 0 companies |